Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Pancreatic Ductal Adenocarcinoma
Clinical trial register · France

Pancreatic Ductal Adenocarcinoma Trials in France, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9726 matching records held by the registry are in this view. Synced 17 Nov 2026, 03:21 UTC
9726
Studies in scope
all four open statuses
6052
Recruiting now
open to new participants
1030
Lead sponsors
across recruiting studies
Top sites
Lyon 8 Villejuif 6 Lille 4 Bordeaux 4 Montpellier 4

Pancreatic Ductal Adenocarcinoma trials in France

18 of 9726 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
NCT06958224Breast Cancer, Liver Cancer, Pancreatic Ductal Adenocarcinoma
University Hospital, Lille
Not applicable
360
Lille
2026-04-29
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NCT07261631Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
180
Vandœuvre-lès-Nancy
2025-11-24
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Astellas Pharma Inc
Phase 1
404
Bordeaux, Lyon, Pierre-Bénite, Villejuif
2025-07-25
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
Verastem, Inc.
Phase 1/2
616
Lyon, Marseille, Paris
2025-06-24
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Eli Lilly and Company
Phase 1
750
Lyon
2024-10-21
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Bron, Villejuif
2024-10-15
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Eli Lilly and Company
Phase 1
630
Lyon, Marseille, Toulouse, Villejuif
2024-09-12
Recruiting
GERCOR - Multidisciplinary Oncology Cooperative Group
Not applicable
72
Dijon, Grenoble, Lille, Marseille, Reims, Rouen, Saint-Cloud, Saint-Herblain
2024-06-24
Active, closed
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Ipsen
Phase 1/2
36
Lyon, Paris, Saint-Herblain, Villejuif
2024-04-03
Recruiting
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
NCT06287749Pancreatic Cancer Resectable, Pancreatic Ductal Adenocarcinoma, Minimal Residual Disease, Liquid Biopsy
University Hospital, Montpellier
Observational
37
Montpellier
2024-03-01
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
Villejuif
2023-11-20
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.
Phase 1/2
534
Angers, Bordeaux, Bron, Lille, Lyon, Montpellier, Nantes, Strasbourg
2023-11-14
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
AstraZeneca
Phase 1/2
392
Toulouse, Villejuif
2023-07-11
Active, closed
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Revolution Medicines, Inc.
Phase 1
222
Angers, Bordeaux, Clermont-Ferrand, Lille, Lyon, Nantes, Strasbourg
2022-09-19
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Panbela Therapeutics, Inc.
Phase 2/3
600
Marseille, Caen, Besançon, Toulouse, Rennes
2022-08-08
Recruiting
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)
NCT05346536Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Circulating Tumor Cell
University Hospital, Montpellier
Not applicable
63
Montpellier
2022-06-16
Active, closed
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
NCT03806309Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2
106
Amiens, Beauvais, Besançon, Bordeaux, Brest, Creil, Créteil, Dijon
2021-04-10
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 November 2026. https://priyalifescience.com/clinical-trials-france/condition/pancreatic-ductal-adenocarcinoma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,726 studies in total at the last sync on 17 Nov 2026, 03:21 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies listing the condition Pancreatic Ductal Adenocarcinoma.

How many Pancreatic Ductal Adenocarcinoma trials are recruiting in France?

12 of the 18 studies on this page are recruiting new participants as of the 17 Nov 2026, 03:21 UTC sync. A further 0 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pancreatic Ductal Adenocarcinoma), 18 studies
PhaseStudiesRecruitingShare
Phase 17438.9%
Phase 1/24322.2%
Not applicable3316.7%
Phase 2/32111.1%
Observational115.6%
Phase 2105.6%

Most active sponsors

Lead sponsors with the most studies (Pancreatic Ductal Adenocarcinoma)
Lead sponsorStudiesRecruiting
Eli Lilly and Company20
GERCOR - Multidisciplinary Oncology Cooperative Group21
Novartis Pharmaceuticals22
Revolution Medicines, Inc.21
University Hospital, Montpellier22
Astellas Pharma Inc11
AstraZeneca11
Bristol-Myers Squibb10
Ipsen10
Panbela Therapeutics, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.